These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Abbott JM; Zhou Q; Esquer H; Pike L; Broneske TP; Rinaldetti S; Abraham AD; Ramirez DA; Lunghofer PJ; Pitts TM; Regan DP; Tan AC; Gustafson DL; Messersmith WA; LaBarbera DV Mol Cancer Ther; 2020 Aug; 19(8):1598-1612. PubMed ID: 32499299 [TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride. Liu LM; Xiong DD; Lin P; Yang H; Dang YW; Chen G Int J Oncol; 2018 Nov; 53(5):1897-1912. PubMed ID: 30132517 [TBL] [Abstract][Full Text] [Related]
5. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer. Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057 [TBL] [Abstract][Full Text] [Related]
6. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity. Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation, structure-activity relationship study, and mode of action of 2-phenol-4,6-dichlorophenyl-pyridines. Shrestha A; Park S; Shin S; Man Kadayat T; Bist G; Katila P; Kwon Y; Lee ES Bioorg Chem; 2018 Sep; 79():1-18. PubMed ID: 29715635 [TBL] [Abstract][Full Text] [Related]
8. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression. Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904 [TBL] [Abstract][Full Text] [Related]
9. Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIα inhibiting anticancer agent. Murugavel S; Ravikumar C; Jaabil G; Alagusundaram P Comput Biol Chem; 2019 Apr; 79():73-82. PubMed ID: 30731361 [TBL] [Abstract][Full Text] [Related]
10. Clarifying the Mechanism of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα and IIβ. Keck JM; Conner JD; Wilson JT; Jiang X; Lisic EC; Deweese JE Chem Res Toxicol; 2019 Oct; 32(10):2135-2143. PubMed ID: 31512855 [TBL] [Abstract][Full Text] [Related]
11. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis. Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892 [TBL] [Abstract][Full Text] [Related]
12. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ. Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062 [TBL] [Abstract][Full Text] [Related]
13. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex. Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804 [TBL] [Abstract][Full Text] [Related]
14. Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile. Khalil OM; Gedawy EM; El-Malah AA; Adly ME Bioorg Chem; 2019 Mar; 83():262-276. PubMed ID: 30391699 [TBL] [Abstract][Full Text] [Related]
15. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014 [TBL] [Abstract][Full Text] [Related]
16. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189 [TBL] [Abstract][Full Text] [Related]
19. PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours. Takihira S; Yamada D; Osone T; Takao T; Sakaguchi M; Hakozaki M; Itano T; Nakata E; Fujiwara T; Kunisada T; Ozaki T; Takarada T Br J Cancer; 2024 May; 130(9):1493-1504. PubMed ID: 38448751 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor. Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]